AMBS - Amarantus BioScience Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.03
0.00 (0.00%)
As of 3:19PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.03
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume486,357
Market Cap6.744M
Beta-2.06
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateAug 18, 2016 - Aug 19, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Amarantus Provides Corporate Update

    NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided a business update on each of its subsidiaries Elto Pharma, Inc., Cutanogen Corporation, NeuroDx (pending formation to develop LymPro Test) and MANF Therapeutics, Inc. In addition, the Company provided guidance on its funding plan to complete its recapitalization and initiate its subsidiary spinoff plan.

  • GlobeNewswire2 months ago

    MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology

    NEW YORK, July 09, 2018-- via OTC PR WIRE-- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. in pre-clinical development advancing the orphan-drug designated therapeutic ...

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Amarantus Bioscience Holdings, Inc.

    NEW YORK, NY / ACCESSWIRE / May 23, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

  • ACCESSWIRE5 months ago

    Amarantus to Present at the Planet MicroCap Showcase 2018 in Las Vegas

    NEW YORK , NY / ACCESSWIRE / April 20, 2018 / Amarantus Bioscience Holdings, Inc. (OTC PINK: AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class ...

  • ACCESSWIRE5 months ago

    SeeThruEquity Issues Update on Amarantus Bioscience Holdings, Inc.

    NEW YORK, NY / ACCESSWIRE / April 10, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...